Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 152 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: OnabotulinumtoxinA (BOTOX®) Clear all
Completed Phase 3 Interventional Results available

BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity

NCT01603641
View directory record Official record
Conditions
Pediatrics, Muscle Spasticity, Cerebral Palsy
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 17 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
26
States / cities
Pasadena, California • Pomona, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults

NCT02191579
View directory record Official record
Conditions
Migraine Disorders
Interventions
onabotulinumtoxinA, Topiramate
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
32
States / cities
Phoenix, Arizona • Encinitas, California • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 17, 2026, 8:14 PM EDT
Recruiting Phase 3 Interventional

BOTOX® vs. XEOMIN® for Chronic Migraine

NCT05598723
View directory record Official record
Conditions
Chronic Migraine
Interventions
IncobotulinumtoxinA (XEOMIN®), OnabotulinumtoxinA (BOTOX®)
Drug
Lead sponsor
Naval Medical Center Camp Lejeune
Federal
Eligibility
18 Years to 89 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

NCT02176356
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
Interventions
onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC
Biological · Drug · Device
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 17, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)

NCT00711087
View directory record Official record
Conditions
Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury
Interventions
BOTOX-A, Saline injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 17, 2026, 8:14 PM EDT
Not listed Phase 1Phase 2 Interventional

ASIS for Botox in Upper Limb Spasticity

NCT02074150
View directory record Official record
Conditions
Upper Limb Spasticity Unilaterally in Adults With History of Stroke, Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
Interventions
Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12,, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
Drug
Lead sponsor
li nguyen
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity

NCT00651729
View directory record Official record
Conditions
Stroke, Muscle Spasticity
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
21 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia

NCT00564681
View directory record Official record
Conditions
Cervical Dystonia
Interventions
botulinum toxin type A, botulinum toxin type A Formulation 2, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

NCT00168428
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum Toxin Type A, placebo (saline)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows

NCT00752258
View directory record Official record
Conditions
Glabellar Rhytides
Interventions
Mentor Purified Toxin Botulinum Toxin Type A
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients

NCT01852045
View directory record Official record
Conditions
Urinary Incontinence
Interventions
OnabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 17, 2026, 8:14 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

NCT04099667
View directory record Official record
Conditions
Spasticity
Interventions
Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity

NCT01852058
View directory record Official record
Conditions
Urinary Incontinence
Interventions
OnabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Results available

OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder

NCT01945489
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, Normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
40
States / cities
Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 17, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional Results available

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

NCT02660138
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence

NCT06387394
View directory record Official record
Conditions
Masseter Muscle Prominence
Interventions
BOTOX, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Results available

Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia

NCT00208091
View directory record Official record
Conditions
Focal Dystonia
Interventions
Botulinum toxin, type B
Drug
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 69 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles

NCT05162300
View directory record Official record
Conditions
Photoaging, Wrinkle, Sun Damaged Skin
Interventions
Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)
Combination Product
Lead sponsor
Vitality Institute Medical Products
Industry
Eligibility
30 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 17, 2026, 8:14 PM EDT
Completed No phase listed Observational Results available

CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy

NCT00836017
View directory record Official record
Conditions
Cervical Dystonia
Interventions
No Intervention
Other
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Results available

The Treatment of Glabellar Frown Lines

NCT02096081
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
IncobotulinumtoxinA, OnabotulinumtoxinA
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

NCT00156910
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum Toxin Type A, Placebo (saline)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 17, 2026, 8:14 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

NCT04815967
View directory record Official record
Conditions
Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury, Cervical Spinal Cord Injury, Cerebral Palsy
Interventions
Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 17, 2026, 8:14 PM EDT
Completed No phase listed Observational

Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

NCT02557971
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
onabotulinumtoxinA
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Davis, California • Irvine, California • Charlotte, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

BOTOX® Treatment in Pediatric Lower Limb Spasticity

NCT01603628
View directory record Official record
Conditions
Pediatrics, Muscle Spasticity, Cerebral Palsy
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 16 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
24
States / cities
Pasadena, California • Pomona, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 17, 2026, 8:14 PM EDT